Search

EHA Kick-off Grant review and selection process

1. Eligibility checkAfter the deadline has passed, we'll check your application for completion and compliance with the eligibility criteria.

Read more

Novel basis for chemoresistance in AML: DNMT3A R882 mutations promote chemoresistance and residual disease through impaired DNA damage sensing

Although most acute myeloid leukemia (AML) patients initially respond to chemotherapy, the majority subsequently relapses and succumbs to refractory disease. Residual leukemic cells that survived chemotherapy may persist over time and later cause the disease to come back.

Read more

New GFI1B variants in bleeding and platelet disorders

Platelets restrict blood loss upon vessel damage by formation of a clot (thrombus). Recently, we reported a family with a bleeding and platelet disorder (BPD), which was caused by a defect in the gene GFI1B1.

Read more

SWG Educational Activities

2023 meetingsThe following EHA-SWG meetings took place in the past calendar year:

54th General Assembly of ERIC members at ELN Symposium 2023
Mannheim, Germany
April 18, 2023

ERIC/Brazilian CLL Group workshop on biomarkers in CLL
Brasilia, Brazil
May 25–26, 2023

55th General Assembly of ERIC members at…

Read more

Highlights from the SWG

The SWG organized a EHA scientific workshop entitled: “Shaping the future of MSC Therapy” in Amsterdam from November 23-25, 2017.

Read more

Registration

Register here

Individual registrationHybrid registration includes:

In-person access to the scientific and educational sessions of the meeting
Meeting materials
Coffee/tea breaks on February 6-8, 2025 and lunches on February 7-8, 2025
Access to the Welcome Reception
Access to the Poster Session(s) and viewing of the physical…

Read more